Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetin - diabetiske neuropatier - psychoanaleptics, - behandling af diabetisk perifer neuropatisk smerte hos voksne.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexoldihydrochloridmonohydrat - restless legs syndrome; parkinson disease - anti-parkinson-lægemidler - mirapexin er indiceret til behandling af tegnene og symptomer af idiopatisk parkinsons sygdom, alene (uden levodopa) eller i kombination med levodopa, jeg. i løbet af sygdommen gennem sene stadier når virkningen af levodopa aftager eller bliver inkonsekvent og udsving i den terapeutiske effekt opstå (slutningen af dosis eller 'on-off' udsving). mirapexin er indiceret til symptomatisk behandling af moderat til svær idiopatisk rastløs-legs syndrome i doser op til 0,. 54 mg base (0. 75 mg salt).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - pramipexoldihydrochloridmonohydrat - restless legs syndrome; parkinson disease - anti-parkinson-lægemidler - sifrol er indiceret til behandling af tegn og symptomer på idiopatisk parkinsons sygdom, alene (uden levodopa) eller i kombination med levodopa, jeg. i løbet af sygdommen, men til de sidste faser, når virkningen af ​​levodopa bærer af eller bliver inkonsekvent, og fluktuationer af den terapeutiske effekt forekommer (end-of-dose eller "on-off" fluktuationer). sifrol er indiceret til symptomatisk behandling af moderat til svær idiopatisk rastløs-legs syndrome i doser op til 0,. 54 mg base (0. 75 mg salt).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

boehringer ingelheim int. gmbh - dipyridamol - depotkapsler, hårde - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

boehringer ingelheim int. gmbh - acetylsalicylsyre, dipyridamol - depotkapsler, hårde - 200 + 25 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - afatinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - giotrif som monoterapi er indiceret til behandling ofepidermal growth factor receptor (egfr) tki-naïve voksne patienter med lokalt fremskreden eller metastatisk ikke-småcellet lungekræft (nsclc) med aktivering af egfr mutation(s);lokalt fremskreden eller metastatisk nsclc af planocellulært histologi skrider på eller efter platin-baseret kemoterapi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrin har vist sig en uge efter primærvaccinationskursus for rhinotracheitis, calicivirus, chlamydophila felis og panleucopenia komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.